Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.3% - Here's Why

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) fell 5.3% on Friday . The company traded as low as $13.55 and last traded at $13.58. 563,568 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 1,179,321 shares. The stock had previously closed at $14.34.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CAPR. Maxim Group upped their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Piper Sandler assumed coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an "overweight" rating and a $35.00 price objective on the stock. Oppenheimer reissued an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald lifted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Trading Down 7.5 %

The firm has a market capitalization of $602.93 million, a P/E ratio of -12.51 and a beta of 3.98. The stock has a 50 day simple moving average of $18.42 and a 200-day simple moving average of $10.04.

Insider Activity at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm's stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock worth $9,274,000 after purchasing an additional 200,499 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Capricor Therapeutics during the 2nd quarter valued at $426,000. Point72 Asset Management L.P. bought a new position in Capricor Therapeutics in the 3rd quarter worth $3,806,000. Finally, Rhumbline Advisers purchased a new stake in Capricor Therapeutics in the 2nd quarter worth $147,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.